Summit Therapeutics Current Cash

Summit Therapeutics posts a current cash of $420M as of June 2026. That compares with $300M in the prior-year period — up 40.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Summit Therapeutics's current cash was $300M. The latest reading is $420M — a 40.8% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of Summit Therapeutics's financial statement story. At $420M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SMMT's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Summit Therapeutics's other metric pages and overview cover the third.